People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| PhaseBio Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $102.1M | $912.3M | 2015 |
| Veralox Therapeutics Inc. | — | Biotechnology | Series B | $39.9M | $272.5M | 2023 |
| Trefoil Therapeutics, Inc. | — | Biotechnology | Series A | $33.3M | $16.2M | 2025 |
Jonathan Mow at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Mow on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clay Thorp | 1 | 10 |
| Christy Shaffer | 1 | 6 |
| Tyrell Rivers | 1 | 6 |
| Justin Klein | 1 | 6 |
| Linda Tufts | 1 | 5 |
| Stella Robertson | 1 | 4 |
| Derek Yoon | 1 | 4 |
| Benjamin Scruggs | 1 | 3 |
| Asish K Xavier | 1 | 3 |
| Christopher Prior | 1 | 3 |
| John Fucci | 1 | 3 |
| Katie Ellias | 1 | 3 |
| Thomas K Laundon | 1 | 2 |
| Alex Martin | 1 | 2 |
| Joel Sussman | 1 | 2 |
| John Sharp | 1 | 2 |
| Douglas K Reed | 1 | 2 |
| Michael K. Gutch | 1 | 2 |
| Ashutosh Chilkoti | 1 | 2 |
| Robert K Ingram | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.